Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | GSK3B | P49841 | 2/20 | 0.48 |
| ▸ | CHEK1 | O14757 | 4/20 | 0.48 |
| ▸ | PSEN1 | P49768 | 4/20 | 0.48 |
| ▸ | PSEN2 | P49810 | 4/20 | 0.48 |
| ▸ | APH1B | Q8WW43 | 4/20 | 0.48 |
| ▸ | NCSTN | Q92542 | 4/20 | 0.48 |
| ▸ | APH1A | Q96BI3 | 4/20 | 0.48 |
| ▸ | PSENEN | Q9NZ42 | 4/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.46 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.45 |
| ▸ | JAK2 | O60674 | 2/20 | 0.44 |
| ▸ | JAK3 | P52333 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19699556 | 0.88 | MAPT (0.57) | MAPTCHEK1ALDH1A1NPSR1 | |
| SCHEMBL19706560 | 0.85 | ADORA2A (0.59) | MTORMAPTGSK3BCHEK1ADORA2A | |
| SCHEMBL25292457 | 0.84 | MTOR (0.53) | MTORMAPTGSK3BCHEK1ALDH1A1 | |
| SCHEMBL19699589 | 0.80 | MAPT (0.45) | MAPTGSK3B | |
| SCHEMBL26550554 | 0.80 | HRH4 (0.59) | CHEK1MAPK10 | |
| SCHEMBL25776011 | 0.79 | PRKDC (0.47) | MTORMAPTGSK3BCHEK1ADORA2A | |
| SCHEMBL19699528 | 0.79 | IDH1 (0.50) | MAPTGSK3B | |
| SCHEMBL25769210 | 0.78 | CHEK1 (0.53) | MTORMAPTCHEK1ALDH1A1MAPK10 | |
| SCHEMBL19392315 | 0.76 | MAPT (0.77) | MAPTALDH1A1NPSR1 | |
| SCHEMBL19699529 | 0.74 | TYK2 (0.45) | MAPTGSK3BALDH1A1MAPK10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170362234-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-12-21 | — | — | US | disclosed |
| US-20170362234-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-12-21 | — | — | US | disclosed |
| US-20170355705-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355705-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | MTOR 395/4885MAPT 306/4885GSK3B 2322/4885 |
| US-20170362234-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | MTOR 363/4885MAPT 290/4885GSK3B 2340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.